X

Trial Profile

A Phase 1/2 Study of Tazemetostat With Umbralisib and Ublituximab in Patients With Relapsed/Refractory Follicular Lymphoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tazemetostat (Primary) ; Ublituximab (Primary) ; Umbralisib (Primary)
Indications Follicular lymphoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

26 May 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
31 Jan 2023 Planned initiation date changed from 15 Dec 2022 to 1 May 2023.
26 Oct 2022 Planned initiation date changed from 15 Sep 2022 to 15 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com